Isoxazole derivatives and methods of treating diseases

1 . A compound having a structure (I):

or a physiologically tolerable salt thereof,

wherein —R is —H, -lower alkyl, —O-lower alkyl, -cyclyhexane, —CH 2 -cyclohexane, —O-cyclohexane, —CH 2 —O-cyclohexane, —C 6 H 5 , —CH 2 —C 6 H 5 , —O—C 6 H 5 or —CH 2 —O—C 6 H 5 .

2 . A pharmaceutical composition comprising the compound of claim 1 or a compound having a structure (II):

or a physiologically tolerable salt thereof.

3 . The pharmaceutical composition of claim 2 wherein the salts comprise sodium salt, ammonium salt potassium salt or combinations thereof.

4 . The pharmaceutical composition of claim 2 wherein the composition is formulated in a dosage form selected from the group consisting of tablets, coated tablets, injectable solutions, suspensions, emulsions, powders, granules, (micro)capsules, suppositories, syrups, lotions, gels, creams, and combinations thereof.

5 . A method of treating a tumor necrosis factor alpha (TNF-α) mediated disorder comprising administering to a patient a therapeutically effective amount of the pharmaceutical composition of claim 2 .

6 . The method of claim 5 wherein the disorder is selected from the group consisting of rheumatoid arthritis, Crohn's disease, psoriasis, lupus, atherosclerosis, scleroderma, multiple sclerosis, Alzheimer's disease, sepsis, type I diabetes, gingivitis, cachexia, and combinations thereof.

7 . A method of treating a Janus Kinase 3 (JAK3) mediated disorder comprising administering to a patient a therapeutically effective amount of the pharmaceutical composition of claim 2 .

8 . The method of claim 7 wherein the disorder is selected from the group consisting of colon cancer, psoriasis, organ transplant rejection, and combinations thereof.